Kenny Workman· kenbwork·· 3 小时前AI 评分58
Latch Bio 推出 TxBench–Antibody Development 基准，评测智能体在抗体开发七阶段的决策能力
Our Antibody Discovery Benchmark asked whether agents could make the decisions that produce a promising candidate. Now we’re following wh...
AI 导读
Latch Bio 推出 TxBench–Antibody Development，一个覆盖治疗性抗体开发七个阶段、共 60 项评估的可验证基准，考察智能体能否做出产生候选药物的决策，并延伸到首次人体剂量等后续环节。
阅读原文
来源：Kenny Workman · x.com